Form 8-K - Current report:
SEC Accession No. 0001193125-25-163815
Filing Date
2025-07-24
Accepted
2025-07-24 07:13:53
Documents
14
Period of Report
2025-07-22
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d57486d8k.htm   iXBRL 8-K 28823
2 EX-99.1 d57486dex991.htm EX-99.1 4571
6 GRAPHIC g57486g0724052719825.jpg GRAPHIC 3143
  Complete submission text file 0001193125-25-163815.txt   154942

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA bmea-20250722.xsd EX-101.SCH 2523
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE bmea-20250722_lab.xml EX-101.LAB 17946
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bmea-20250722_pre.xml EX-101.PRE 11243
16 EXTRACTED XBRL INSTANCE DOCUMENT d57486d8k_htm.xml XML 3719
Mailing Address 1599 INDUSTRIAL ROAD SAN CARLOS CA 94070
Business Address 1599 INDUSTRIAL ROAD SAN CARLOS CA 94070 (650) 980-9099
Biomea Fusion, Inc. (Filer) CIK: 0001840439 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40335 | Film No.: 251144509
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)